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Abstract
During the development of rheumatoid arthritis (RA) autoantibodies
to IgG-Fc, citrullinated proteins, collagen type II (CII), glucose 6
phosphoisomerase (G6PI) and some other self-antigens appear.
Of these, a pathogenic effect of the anti-CII and anti-G6PI
antibodies is well demonstrated using animal models. These new
antibody mediated arthritis models have proven to be very useful
for studies involved in understanding the molecular pathways of
the induction of arthritis in joints. Both the complement and FcγR
systems have been found to play essential roles. Neutrophils and
macrophages are important inflammatory cells and the secretion of
tumour necrosis factor-α and IL-1β is pathogenic. The identification
of the genetic polymorphisms predisposing to arthritis is important
for understanding the complexity of arthritis. Disease mechanisms
and gene regions studied using the two antibody-induced arthritis
mouse models (collagen antibody-induced arthritis and serum
transfer-induced arthritis) are compared and discussed for their
relevance in RA pathogenesis.
Introduction
Both genetic and environmental factors interact and
contribute to the development of autoimmune diseases. One
such disease debilitating joint architecture is rheumatoid
arthritis (RA). Arthritis in the joint involves a multicellular
inflammatory process, including infiltration of lymphocytes
and granulocytes into the articular cartilage, proliferation of
synovial fibroblasts and macrophages and neovascularization
of the synovial lining surrounding the joints. This proliferative
process not only induces swelling, erythema, and pain in
multiple joints but also progresses to joint destruction and
causes loss of bone density and architecture. Many cellular
components (macrophages, dendritic cells, fibroblast-like
synoviocytes, mast cells, eosinophils, neutrophils, T cells and
B cells), cell surface molecules (adhesion molecules,
integrins), signaling components (ZAP70, PTPN22, JAK,
mitogen activated protein kinase and Stat1) and humoral
mediators (antibodies, cytokines, chemokines, metallo-
proteinases, serine proteases and aggrecanases) interact
and aid in the disease progression, leading to digestion of
extracelluar matrix and destruction of articular structures.
The importance of B cells in RA pathogenesis stems not only
from the original finding of high titers of rheumatoid factors
(RFs), but also from the observation that arthritis is mediated
in experimental animals via B cells and anti-collagen type II
(anti-CII) antibodies [1-5]. Interest in studying the role of B
cells in arthritis has returned as a result of successful anti-
CD20 therapy [6-8]. In addition, the two widely used mouse
models of antibody-initiated arthritis, collagen antibody-
induced arthritis (CAIA; induced with anti-CII antibodies) and
the newly developed serum transfer-induced arthritis (STIA;
induced with anti-glucose 6 phosphoisomerase (anti-G6PI)
anti-sera) have been better characterized. B cells can
contribute to the disease pathogenesis as antigen presenting
cells, through costimulatory functions (surface molecules and
secreted cytokines), by supporting neolymphogenesis, as
well as through its secretory products, immunoglobulins. In
RA, autoantibodies provide diagnostic and prognostic
criteria, and serve as surrogate markers for disease activity
(RFs, anti-citrullinated protein antibodies (ACPAs)), and may
play a requisite role in disease pathogenesis (anti-CII and
anti-G6PI antibodies).
The contributions of antibodies to the disease are initiated by
their direct binding to their respective antigens and involve
immune complex formation, deposition, and activation of
complement and Fc receptors (FcRs). Modulation of
circulating immune complexes and pathogenic antibodies by
simple removal using therapeutic plasmapheresis or
depleting B cells with the antibody rituximab acting via
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complement-dependent and antibody-dependent cell-
mediated cytotoxicity through the induction of apoptosis and
inhibition of cell growth proved to be beneficial [9]. In RA
patients, prevalence of anti-G6PI antibodies is low and may
occur in only severe RA [10]. Levels of anti-CII antibodies are
more commonly detected; however, varying levels of
prevalence of anti-CII antibodies in RA that are dependent on
the nature and source of CII used for assay and the phase of
the clinical disease have been observed. For example,
seropositivity for antibodies to native CII (approximately 14%
to 48%), denatured CII (approximately 50% to 87%), and
cyanogen bromide fragment 10 (CB10; 88%) were observed
in RA patients’ sera [11-15]. Similarly, the IgM antibody
against the Fc part of the IgG antibodies (RF) has been
consistently associated with RA (80% seropositivity), but it
has also been reported to be present in normal individuals as
well as during other chronic inflammatory conditions [16].
The importance of RF in RA is yet to be clearly ascertained. It
can form immune complexes in the joint that could fix
complement and release chemotactic factors, such as C5a,
which in turn could attract neutrophils. Activated neutrophils
can ingest immune complexes, releasing various proteases
and oxidative radicals that destroy the cartilage matrix. The
synovium itself is a rich source for the production of
complement proteins and RF [17]. On the other hand, RF can
also protect the joint by masking the epitopes from the
arthritogenic antibody binding. Similarly, ACPAs have been
shown to be specifically present in RA patients [18].
However, as with RF, it is not yet known if ACPAs are merely
a consequence of the inflammatory process rather than being
responsible for initiating or perpetuating it [19]. Although
ACPAs were not detectable in earlier studies with collagen-
induced arthritis (CIA) [20,21], a recent study reported the
presence of these antibodies during the early phase of CIA
[22]. Furthermore, an anti-cyclic citrullinated peptide mono-
clonal antibody (mAb) was shown to enhance the arthritis
severity induced by an anti-CII mAb cocktail [22], suggesting
ACPAs contribute to the severity of the disease. It is not yet
clear, however, whether the induction of arthritis is due to the
binding of citrullinated epitopes or cross-reactivity to other
epitopes within the joints.
The importance of Ig glycosylation status on its biological
function and structure has been reviewed in detail [23]. An
association between RA and an increase in IgG glycoforms
lacking galactose in the Fc region has been demonstrated
[24,25], which correlated with disease activity [26].
Subsequently, passive transfer of an acute synovitis in T-cell-
primed mice was reported to be enhanced by an agalactosyl
glycoform of anti-CII antibodies [27]. Recent studies also
demonstrate the impact of differential Fc sialylation on pro- or
anti-inflammatory activities of IgG [28].
Need for animal models
A basic understanding of disease mechanisms is a
prerequisite for finding effective therapy with minimized side
effects. Animal models provide opportunities for detailed
analysis of similar disease pathways operating during early,
intermediate and late stages of the development of human
arthritis, although they will not be identical to those of RA. On
the other hand, RA itself is not a single disease but a
syndrome that includes different disease phenotypes. Thus,
one should look for similar or common disease pathways
involved in the disease development.
Collagen antibody-induced arthritis
Immunization of rodents and primates with CII in adjuvant
induced an autoimmune arthritis, the so called CIA that, in
many ways, resembles RA [29-32]. CII is the major
constituent protein of the cartilage of diarthrodial joints, the
site of inflammation in RA, and immunity to CII can be
detected in RA patients [11,12,33-36]. The major B cell
epitopes are spread over the triple helical part of CII
(cyanogen bromide (CB) fragments 8 to 11). The B cell
hybridomas generated in our lab against CII mainly
recognized six major epitopes (J1, C1III, U1, D3, F4 and E8);
mAbs to these epitopes have been well characterized
[37-44]. Single or combinations of these mAbs induced
arthritis in naïve mice [5,45-47]. In vitro studies with anti-CII
mAbs showed that these antibodies could be pathogenic to
chondrocytes even in the absence of inflammatory
mediators, being involved in impaired cartilage formation
[48], strong inhibition of collagen fibrillogenesis [49] and
disorganization of CII fibrils in the extracellular matrix with or
without increased matrix synthesis [50]. Furthermore, these
mAbs also had deleterious effects on the pre-formed
cartilage [51]. These findings show that the antibodies
initiate the pathogenic events even before the inflammatory
phase.
Arthritis can be transferred to naïve mice using serum from
arthritic mice [1,52] or a human RA patient [53], or with a
combination of CII-specific mAbs [2,3,5] or a single mAb
[45]. Arthritis produced by passive transfer of CII mAbs
resembles actively induced CIA but in an acute form
(Figure 1) with a much more rapid onset (24 to 48 hours).
Usually, arthritis subsides completely after a month and mice
become normal. Lipopolysaccharide enhances the incidence
and severity of the antibody initiated disease by decreasing
the threshold for arthritis induction, bypassing epitope
specificity, and increasing pro-inflammatory mediators and
activation of complement components via toll-like receptor 4
signaling [3,5,54]. It is also possible to induce relapses with
single mAbs in the mice that had previously developed
chronic CIA [44], demonstrating the role of antibodies in
relapses during the chronic phase of arthritis. Cartilage
disrupted as a result of genetic disorders could be more
accessible and vulnerable to an autoimmune attack by
pathogenic antibodies, which was emphasized by the recent
observations of enhanced cartilage-specific antibody binding
and, thus, arthritis severity in mice with collagen type IX
deficiency [55].Page 3 of 11
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CAIA susceptibility is major histocompatibility complex
(MHC) independent [1,5]. Severe combined immunodeficient
(SCID) mice develop arthritis [56], as do T or B cell deficient
mice, but T and B cell double deficient mice have less severe
arthritis [46], suggesting a regulatory role for these cells at
the effector level. Cytokines and their interacting functional
capabilities play a pivotal role in the development of RA. The
pro-inflammatory cytokines tumour necrosis factor (TNF)-α
and IL-1 are critical mediators in the inflammatory process of
arthritis [57,58], and neutralizing these effector cytokines has
proven successful in the treatment of RA. Like RA, the
inflammatory response in the arthritic mouse joint is
predominantly mediated by these pro-inflammatory cytokines
[59], all of which have been successfully targeted to down-
regulate the disease [60]. These antigen-presenting cell-
derived cytokines and chemokines (TNF-α, IL-1β and
macrophage inflammatory protein (MIP)-1α, but not IL-6)
have been reported to be required for CAIA induction as well
[56]. Overexpression of oncostatin M in the mouse joints
induced synovial pathology [61] and anti-oncostatin M
treatment suppressed arthritis [62], except in one study in
which human oncostatin M treatment was shown to inhibit
CAIA [63]. However, human but not mouse oncostatin M
binds the leukocyte migration inhibitory factor receptor and
human oncostatin M did not bind to the mouse oncostatin M
receptor [64]. Recently, the transcription factor T-bet has
been shown to modulate antibody-induced arthritis through
its regulatory function on IL-1β and chemokine production by
dendritic cells [65]. On the other hand, T cell secreted
cytokines could be detrimental or protective to the joints,
perhaps depending on the phase of the clinical disease. IL-4
is perceived as an anti-inflammatory cytokine; however, under
certain circumstances it may function as a pro-inflammatory
cytokine. Earlier, we found that IL-4 deficiency protected mice
from CAIA [66,67]. Neutralization of interferon-γ relieved the
suppression of antibody mediated arthritis induced by anti-
IL-4 treatment [67] and IL-10 promoted the disease in the
B10.Q genetic background [68]. Interferon-β deficiency
exacerbated the disease; stromal cells and osteoclasts might
be responsible for this [69]. Thus, efforts to counteract the
pre-existing inflammatory cytokines in RA patients by inducing
anti-inflammatory cytokines or neutralizing pro-inflammatory
cytokines should be critically evaluated before considering
this form of therapy.
Depletion of neutrophils significantly reduced the severity of
CAIA [5], while disruption of the gp49B gene enhanced the
disease [70]. A positive regulatory role for CD69 in neutrophil
function during arthritis induction in CAIA was reported [71],
but a recent study ruled out such a significant stimulatory role
for it [72]. Antileukoproteinase, an inhibitor of neutrophil
protease, completely abolished the disease [73] by inhibiting
leukocyte attachment to the synovial endothelium [74], but
the disease modifying anti-rheumatic drug methotrexate did
not [75]. Transdermal photodynamic therapy reduced the
clinical arthritis and synovial inflammation in CAIA [76].
Macrophage migration inhibitory factor induces the
production of a large number of pro-inflammatory molecules
and may have an important role in the pathogenesis of RA by
promoting inflammation and angiogenesis. Deficiency in it
decreased arthritis development significantly, possibly via
Available online http://arthritis-research.com/content/8/6/223
Figure 1
Antibody-mediated arthritis in mice. (a) Collagen antibody-induced arthritis disease curve in BALB/c mice. A cocktail of arthritogenic mAb (M2139
+ CIIC1), isotype control (L243 + G11) or phosphate-buffered saline (PBS) was intravenously injected on day 0 (n = 10 to 12). All the mice
received lipopolysaccharide (50 µg/mouse intraperitoneally) on day 5. Arthritis was monitored for 30 days. None of the control mice developed
arthritis. Clinical arthritis on day 10 was shown (b) after antibody transfer in B10.RIII mice (left, normal paw; right, arthritis paw), and (c) after
antibody transfer and lipopolysaccharide injection in BALB/c mice (left, arthritis paw; right, normal paw). N, number of mice in each group. Error
bars denote standard error of the mean.matrix metalloproteinase (MMP)13 and neutrophil infiltration
through MIP-2 [77]. Similarly, MIP-1 family members
orchestrate inflammatory host responses mainly by recruiting
pro-inflammatory cells, and MIP-1α (CCL3) null mice were
found to be protected from CAIA [78]. Plasminogen deficient
mice were resistant to CAIA but, upon reconstitution with
plasminogen, arthritis was restored, demonstrating that active
plasmin is essential for the pathology [79]. Dipeptidyl
protease I and two of its substrates, neutrophil elastase and
cathepsin G, contribute to joint inflammation [80]. Interest-
ingly, reduced arthritis severity was observed in both the α1-
integrin deficient mice and in the naïve mice pre-treated with
an α1 integrin blocking mAb [81]. Nitric oxide synthesized by
nitric oxide synthases is implicated in the pathogenesis of
arthritis. However, in CAIA, deletion of the gene encoding
nitric oxide synthase-2 did not affect inflammation, although
cartilage degradation was reduced substantially [82]. On the
other hand, cyclooxygenase (COX)2 is a key enzyme involved
in the metabolism of arachidonic acid to prostaglandin H2,
which is converted to biologically active prostaglandins
(PGs), such as PGE2. COX2 is critical for arthritis induction
[83]. Furthermore, the PGE2 receptor EP4, but not EP1, EP2
and EP3, is essential in CAIA [84], whereas microsomal PGE
synthase 1 deficient mice [85] and prostacyclin (PGI2)
receptor deficient mice [86] had reduced arthritis.
Interestingly, MMP2 and MMP9 had opposite roles [87],
JNK-2 (c-Jun amino-terminal kinase-2) is not critical [88] and
the role of osteopontin is still controversial [89,90].
Antibodies, particularly as constituents of immune complexes,
play a central role in triggering inflammation in a number of
autoimmune diseases [91]. It has been proposed that
immune complexes initiate inflammatory responses either via
activation of the complement system [92] or, alternatively, by
the direct engagement and activation of FcR-bearing inflam-
matory cells [93]. Several factors could influence the relative
contributions of complement versus FcR inflammatory
pathways to the immune complex-triggered inflammatory
response. These include antibody isotype and titer as well as
the site of immune complex deposition. With respect to the Ig
isotype, FcR mechanisms could predominate, with immune
complexes comprising non-complement-fixing antibodies, or,
after deposition, in sites with abundant resident FcR-bearing
inflammatory cells. Conversely, complement-driven inflamma-
tion may dominate when immune complexes containing Ig-
constant regions are poorly bound by FcR or when leuko-
cytes must be attracted to an inflammatory site. In addition,
antibody titer may influence humoral pathways of inflam-
mation. For example, it has been shown that the complement
dependence of antibody-mediated renal inflammation is lost
at higher antibody doses [94].
Immunoglobulins mediate pro- and anti-inflammatory activities
through the engagement of their Fc fragment with distinct
FcγRs. In CAIA, mice lacking the common FcRγ-chain are
highly resistant [45,95], but FcγRIII deficient mice are only
partially resistant [95]. Absence of FcγRIIb in DBA/1 mice
exacerbates the disease [45], but this is not the case in the
BALB/c background [95]. More rapid and severe arthritis
was observed with single injection of anti-CII mAbs in Tg
mice expressing human FcγRIIa [96].
Complement components could play several important roles
in the antibody-mediated disease, such as: opsonization for
effective phagocytosis; in immune complex clearance (C3b
and C4b) by binding to complement receptors on red blood
cells, which transport the complexes to the liver and spleen
where they give the complexes up to phagocytes for
destruction; as inflammatory activators (C5a, C4a and C3a)
inducing vascular permeability, recruitment and activation of
phagocytes; and in lysis (membrane attack complex).
Complement factor 3 and, to an extent, factor B [97], C5
[98,99] (KS Nandakumar and colleagues, unpublished
observations) and C5aR [100] are required in recipient mice.
Deposits of IgG and C3 are found after the serum transfer
[1]. Interestingly, C3 depletion of recipient rats with cobra
venom factor prevented passive transfer of arthritis with anti-
CII antibodies [101]. Similarly, C3 deficient mice developed
less severe disease compared to C3 sufficient mice, although
both systemic and local C3 and C5 cleavage would be
absent in these mice [97]. In immune complex diseases, C3
is important in both dissociating larger complexes into smaller
units and mediating removal of complexes through the
clearance pathway involving erythrocyte or platelet immune
adherence receptors [102]. Lack of sufficient C3 may lead to
a redistribution of immune complexes into tissues, with
activation of other pathways of inflammation. However, C3
inhibition/deletion targeted to the site of tissue injury may
provide considerable local anti-inflammatory effects without
the possible complications of systemic complement depletion
[103], apart from complete inhibition of the complement
cascade. Furthermore, arthritis did not develop in C5-
deficient B10.D2 mice after passive transfer of anti-CII
antibodies, in spite of abundant IgG and C3 deposition on
the cartilage surface [104]. Similarly, C5 deficient congenic
animals did not develop the antibody-initiated disease (KS
Nandakumar and colleagues, unpublished observations). The
C5 breakdown product, C5a, is the most potent anaphyla-
toxin and a powerful chemotaxin for neutrophils and mono-
cytes, with the ability to promote margination, extravasation,
and activation of these cells [105]. Activation by C5a induces
the release of multiple additional inflammatory mediators
[106]. C5a levels are markedly elevated in the synovial fluids
of patients with RA [107], and a selective C5a receptor
antagonist is inhibitory to immune complex-induced inflam-
mation [108]. It is of interest to note that both the
anaphylotoxins C3a and C5a induce translation of IL-1 and
TNF-α (effector cytokines in CAIA) in monocytes, but
transcription requires an additional signal, such as
lipopolysaccharide or IL-1 itself [109,110]. Presumably,
inflammatory cell recruitment to the joint by C5a or other
complement-induced chemotactic factors might be required
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Page 4 of 11
(page number not for citation purposes)for disease initiation. Interestingly, C5a binding to C5aR
induces the expression of activating FcγRIII while down-
modulating inhibtory FcγRII on macrophages, which
demonstrates how these two key components of acute
inflammation can interact with each other in vivo [111].
Recently, it has also been shown that C5a can down-
modulate toll-like receptor-4-induced immune responses
[112], indicating the complexity of interactions in the immune
response. The possible interactions of immune effector cells
in the inflammatory phase of the arthritic joint are depicted in
Figure 2.
KBN mice and serum transfer-induced
arthritis
The F1 progeny (KBN) of KRN T cell receptor (TCR)
(recognizing bovine RNase presented by Ak) transgenic mice
and non-obese diabetic (NOD) mice carrying the MHC class
II allele Aβg7 spontaneously develop severe peripheral arthritis
beginning at about three weeks of age [113]. T and B cell
autoimmunity to the ubiquitous glycolytic enzyme G6PI was
found to be the driving force in this disease model.
Appearance of KRN transgenic T cells in the periphery
correlated with disease onset [113,114]. The KRN TCR
recognizes a peptide derived from G6PI (residues 282 to
294) in the context of Aβg7 [115,116]. After the initiation, the
disease proceeds due to the presence of high levels of anti-
G6PI antibodies. It was clearly shown that the arthritis was
mediated by G6PI antibodies [115]. The development of
arthritis in the KBN mice, but not the anti-G6PI serum-
induced arthritis, is critically dependent on IL-4 [117],
explaining the dominance of antibodies of the IgG1 isotype
specific for G6PI. Neutralization of TNF-α (starting at three
weeks of age) did not prevent the disease in KBN mice
[118]. Recently, it has been shown that immunization with
recombinant G6PI-induced arthritis in naïve mice [119], and
that a genetically dependent chronic arthritis eventually
developed [120].
Naïve mice injected with KBN serum [121], affinity-purified
polyclonal anti-GP6I antibodies [115] or a combination of
two or more anti-G6PI mAbs [122] induced arthritis. Purified
anti-G6PI transferred into the mice localized specifically to
distal joints in the front and rear limbs within minutes of
injection, saturated within 20 minutes and remained localized
for at least 24 hours [123]; the accumulation of immune
complexes seems to be possible due to the lack of decay-
accelerating factor in this tissue [124]. The predominant
isotype of the antibodies present in the KBN serum is γ1 and
severe arthritis is maintained if repeated injections of serum
are given [121]. Degranulation of mast cells was apparent
Available online http://arthritis-research.com/content/8/6/223
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Figure 2
Possible interactions of effector molecules in the collagen antibody-induced arthritis joint. AA, arachidonic acid; C1q, C2a, C3, C3a, C4b, C5a and
B (factor B), complement components; CCL3, chemokine (C-C motif) ligand 3; COX2, cyclooxygenase-2; EP4, prostaglandin receptor; FcγR, Fcγ
receptor; IC, immune complex; IL, interleukin; LTB4, leukotriene B4; Mφ, macrophages; M, mast cells; MIF, macrophage migration inhibitory factor;
N, neutrophils; PGE2, prostaglandin E2; TGF, transforming growth factor; TNF, tumour necrosis factor.within an hour [125] and influx of neutrophils was prominent
within one to two days [126]; synovial hyperplasia and mono-
nuclear cell infiltration, with pannus formation and erosion of
bone and cartilage, began within a week [121,126].
Arthritis caused by KBN serum transfer is MHC independent.
Also, T and B cells are not required since arthritis developed
in RAG1-/- mice [121]. A single injection of anti-G6PI
antibody caused prolonged and more severe arthritis in B
cell-deficient (µMT) KBN mice [121]. Mice depleted of
neutrophils using anti-Gr-1 (RB6) antibodies are resistant
[126] and neutrophil expression of leukotriene B4 receptor
BLT1 was reported to be absolutely required for arthritis
generation and chemokine production in this model [127].
Similarly, mice lacking macrophage-like synoviocytes (op/op
mice) are not susceptible [128]. In addition, mice depleted of
macrophages by clodronate liposome treatment were
completely resistant. Reconstituting these mice with macro-
phages from naïve animals reversed this resistance [129]. A
recent report implicated a novel role for cyclin-dependent
kinase inhibitor p21 in regulating the development and/or
differentiation of monocyte populations that might be crucial
for the induction of inflammatory arthritis [130]. Furthermore,
CD40L deficient mice were resistant [118]. Intravenous
immunoglobulin (IVIG)-induced expression of FcγRIIB in
macrophages but not in neutrophils protected the mice from
the disease. Arthritis induction but not IVIG protection was
observed in colony stimulating factor-1-deficient mice
(op/op), demonstrating that colony stimulating factor-1-
dependent macrophages were responsible for IVIG
protection in this antibody-induced arthritis model [128].
Mice having mutations in the stem cell factor receptor, c-kit
(W/Wv), or its ligand, stem cell factor (Sl/Sld), leading to mast
cell deficiency, are resistant, and susceptibility can be
restored by reconstitution with mast cell precursors
[125,131].
TNF-α- and IL-1R- but not IL-6-deficient mice were resistant
to disease induction by KBN serum [132,133], but TNF
receptor 1- and TNF receptor 2-deficient mice were
susceptible [132]. IL-4 is dispensible for STIA [117]. Gene-
disrupted or congenic mice were used to delineate the roles
of complement components: factor B, C3, C5 and C5aR are
essential, but not C1q, C4, mannose binding lectin-1, C6,
CR1, CR2, and CR3 [134,135]. Thus, it has been concluded
that activation through the alternative pathway leading to the
generation of C5a is important in STIA. Mice lacking the
common chain FcRγ were reported to be more resistant than
those lacking only FcγRIII [134]. Different results were
obtained with FcγRII-deficient mice; either they had no effect
[134], or had an earlier onset and greater severity of disease
after KBN serum transfer [131]. The neonatal MHC-like FcR
(FcRn) is also required for the antibody transferred disease
and resistance is associated with a very short circulating half-
life of the transferred antibodies [136]. Natural-killer T cells
promoted this antibody-mediated inflammation [137].
Recently, a genetic polymorphism of the IL-1β gene was
shown to be important in the serum transferred disease
[138]. Interestingly, IVIG treament or anti-murine albumin
antibodies protected mice against KBN serum-induced
arthritis [139], suggesting the importance of FcR interactions
in arthritis pathogenesis. Recently, anatomically restricted
macromolecular vasopermeability dependent on vasoactive
amines has been shown as one of the bases for the
selectivity of the immune complex-facilitated antibody access
to the joints [140]. Furthermore, a role for the pro-apoptotic
Bcl-2 protein Bim, but not Bak and Bax, in the effector phase
of RA was also demonstrated [141].
A comparison between CAIA and STIA
It is clear that antibody-induced arthritis induced with
antibodies to CII shares many characteristics with that
induced with G6PI. There are, however, some differences,
although a direct experimental comparison has not yet been
published, and most data for CAIA have been generated with
purified mAbs specific for CII epitopes whereas data on STIA
were generated with highly arthritogenic sera from the KBN
mouse. Another limitation is that most studies with STIA use
IgG1 antibodies whereas studies of CAIA involve antibodies
of other IgG isotypes. This could possibly explain why STIA is
exclusively dependent on the alternative complement
pathway, whereas in the induction of CAIA both the classic
and alternative pathway may occur. It might also explain the
different results with respect to the dependence on FcR in
the two models. Anti-G6PI serum is clearly more effective at
inducing arthritis than anti-CII mAbs. This could be due to the
polyclonality of the anti-G6PI serum as anti-G6PI mAb
transfer also seems to be less efficient. In addition, different
anti-CII antibodies have different arthritogenicity, related to
their epitope specificity, and it is likely that the optimal mAbs
have not yet been identified. Obviously, the anti-G6PI and
anti-CII antibodies have different antigen specificity and this
leads to different localization in the joints. Both types of
antibody rapidly bind to the cartilage surface in vivo
[38,40,123], but arthritogenic anti-CII antibodies penetrate
the cartilage to reach chondrocytes [51], whereas the anti-
G6PI antibodies also bind to synovial tissue [142]. The
functional consequence is, however, not clear but it is
possible that anti-CII antibodies cause pathology even before
activating the inflammatory response.
Arthritis quantitative trait loci map
Identification of gene regions promoting and inhibiting
arthritis will ultimately not only unravel the candidate genes
but also help to dissect the molecular pathways involved in
the disease pathogenesis. Earlier, we identified the biological
significance of the genetic contamination present in the MHC
congenic mouse strains in a locus on chromosome 10. The
contaminating RIIIS/J gene region present in chromosome 10
and 17 promoted CAIA [143], whereas in the congenic
mouse strain the RIIIS/J gene fragment on chromosome 3
inhibited it [144]. The NOD gene region on chromosome 2,
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chromosome 1, containing FcγRs, influenced both antibody-
induced arthritis models [114] (unpublished observations).
Several different mouse crosses were used in different
arthritis models to identify arthritis associated quantitative
trait loci (QTL). Arthritis QTL identified so far [145] using
various arthritis mouse models are summarized in Figure 3.
Interestingly, many of these gene regions are located densely
in just a few chromosomes, suggesting that the identified
QTL might represent complex loci containing various
genomic variants, each of which functions individually or
through interactions to modulate disease phenotypes in each
of the different models. Alternatively, they may also represent
single polymorphic alleles that regulate disease expression by
a similar mechanism in multiple models, as is proposed by
studies with experimental models of insulin-dependent
diabetes mellitus and autoimmune encephalomyelitis [146].
For some complex QTL, the responsible polymorphism may
reside within a regulatory locus or an encoded transcription
factor that governs the simultaneous up-regulation or down-
modulation of several genes with the capacity to alter
inflammation and autoimmunity [147].
Lessons from animal studies
Animal models for arthritis reveal that breakdown of tolerance
by disruption of homeostasis or active immunization leads to
disease development in which both T and B cells are
essential, but not when preformed antibodies or T cells are
used for disease induction. Antibody-induced arthritis models
provide an opportunity to study the inflammatory phase of
arthritis without involving the priming phase of the immune
response. At the effector level, different pathways of
complement activation and FcγR engagement are necessary
for clinical disease. The fact that the common γ-chain of the
FcR promotes arthritis while FcγRIIb is inhibitory is now
clearly demonstrated. Recently, IgG2a and IgG2b antibody
binding common γ-chain dependent activating Fc receptor
(FCγRIV) that maps in between FcγRII and FcγRIII on
chromosome 1 has been indentified [148]. More studies are
needed to address the importance of FcRIV in different
arthritis models. Antigen-presenting cell-derived cytokines,
TNF-α and IL-1β, have been proved to be important for
arthritis induction and perpetuation. T cell secreted cytokines
could be detrimental or protective to the joints, possibly
depending on the phase of the clinical disease. Effector cells
of the innate immune system (neutrophils, macrophages and
mast cells) drawn to the inflammatory foci by different
chemokines and chemoattractants are actively engaged in
these models to induce inflammation, inflict damage on the
cartilage and perpetuate the ongoing immune responses by
secreting cytokines and proteases. Once the stimuli (anti-CII
antibodies in the case of CAIA) have been nullified, the
mouse recovers. However, if epitope spreading and release
of unexposed antigens or antigenic modifications continue
within the joint it may drive the disease to the chronic stage,
with complete distruption of joint architecture. Thus,
dissecting the fine specificity of the molecules taking part in
the pathogenesis and understanding both the upstream and
downstream molecular events involved in the disease
process using animal models would be more interesting and
valuable for effective development of therapeutic strategies.
With the recent advances in our knowledge and techniques
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Figure 3
Gene regions in mouse that promote (P) or inhibit (I) collagen antibody-induced arthritis (CAIA). CAIA was promoted by NOD (cia 9 quantitative
trait locus (QTL)) and RIIIS/J (cia 8 and cia 1 QTL) genes, and inhibited by NOD (cia 2 QTL) and RIIIS/J (cia 5 QTL) genes. Disease modulating
QTL from other arthritis mouse models are given in the background to demonstrate the co-localization of QTL. Bbaa, Borrelia burgdorferi-
associated arthritis; Cia, collagen-induced arthritis; Erars, erosive arthritis susceptibility; Laq, lupus-associated arthritis QTL; Paam, progression of
autoimmune arthritis in MRL mice; Pgia, proteoglycan-induced arthritis; STIA, serum transfer-induced arthritis.in various scientific disciplines, the possibility of developing
novel therapies for RA is all the more promising.
Competing interests
The authors declare that they have no competing interests.
References
1. Stuart JM, Dixon FJ: Serum transfer of collagen-induced arthri-
tis in mice. J Exp Med 1983, 158:378-392.
2. Terato K, Hasty KA, Reife RA, Cremer MA, Kang AH, Stuart JM:
Induction of arthritis with monoclonal antibodies to collagen. J
Immunol 1992, 148:2103-2108.
3. Terato K, Harper DS, Griffiths MM, Hasty DL, Ye XJ, Cremer MA,
Seyer JM: Collagen-induced arthritis in mice: synergistic effect
of E. coli lipopolysaccharide bypasses epitope specificity in
the induction of arthritis with monoclonal antibodies to type II
collagen. Autoimmunity 1995, 22:137-147.
4. Svensson L, Jirholt J, Holmdahl R, Jansson L: B cell-deficient
mice do not develop type II collagen-induced arthritis (CIA).
Clin Exp Immunol 1998, 111:521-526.
5. Nandakumar KS, Svensson L, Holmdahl R: Collagen type II-spe-
cific monoclonal antibody-induced arthritis in mice: descrip-
tion of the disease and the influence of age, sex, and genes.
Am J Pathol 2003, 163:1827-1837.
6. Edwards JC, Cambridge G: Sustained improvement in rheuma-
toid arthritis following a protocol designed to deplete B lym-
phocytes. Rheumatology (Oxford) 2001, 40:205-211.
7. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska
A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-
targeted therapy with rituximab in patients with rheumatoid
arthritis. N Engl J Med 2004, 350:2572-2581.
8. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J,
Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF,
Li NF, Agarwal S, et al.: The efficacy and safety of rituximab in
patients with active rheumatoid arthritis despite methotrexate
treatment: results of a phase IIB randomized, double-blind,
placebo-controlled, dose-ranging trial. Arthritis Rheum 2006,
54:1390-1400.
9. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R,
Newman RA, Hanna N, Anderson DR: Depletion of B cells in
vivo by a chimeric mouse human monoclonal antibody to
CD20. Blood 1994, 83:435-445.
10. Matsumoto I, Lee DM, Goldbach-Mansky R, Sumida T, Hitchon
CA, Schur PH, Anderson RJ, Coblyn JS, Weinblatt ME, Brenner
M, et al.: Low prevalence of antibodies to glucose-6-phos-
phate isomerase in patients with rheumatoid arthritis and a
spectrum of other chronic autoimmune disorders. Arthritis
Rheum 2003, 48:944-954.
11. Wooley PH, Luthra HS, Krco CJ, Stuart JM, David CS: Type II
collagen-induced arthritis in mice. II. Passive transfer and
suppression by intravenous injection of anti-type II collagen
antibody or free native type II collagen. Arthritis Rheum 1984,
27:1010-1017.
12. Cook AD, Rowley MJ, Stockman A, Muirden KD, Mackay IR:
Specificity of antibodies to type II collagen in early rheuma-
toid arthritis. J Rheumatol 1994, 21:1186-1191.
13. Cook AD, Rowley MJ, Mackay IR, Gough A, Emery P: Antibodies
to type II collagen in early rheumatoid arthritis. Correlation
with disease progression. Arthritis Rheum 1996,  39:1720-
1727.
14. Cook AD, Mackay IR, Cicuttini FM, Rowley MJ: IgG subclasses
of antibodies to type II collagen in rheumatoid arthritis differ
from those in systemic lupus erythematosus and other con-
nective tissue diseases. J Rheumatol 1997, 24:2090-2096.
15. Cook AD, Stockman A, Brand CA, Tait BD, Mackay IR, Muirden
KD, Bernard CC, Rowley MJ: Antibodies to type II collagen and
HLA disease susceptibility markers in rheumatoid arthritis.
Arthritis Rheum 1999, 42:2569-2576.
16. Newkirk MM: Rheumatoid factors: host resistance or autoim-
munity? Clin Immunol 2002, 104:1-13.
17. Neumann E, Barnum SR, Tarner IH, Echols J, Fleck M, Judex M,
Kullmann F, Mountz JD, Scholmerich J, Gay S, et al.: Local pro-
duction of complement proteins in rheumatoid arthritis syn-
ovium. Arthritis Rheum 2002, 46:934-945.
18. van Venrooij WJ, Pruijn GJ: Citrullination: a small change for a
protein with great consequences for rheumatoid arthritis.
Arthritis Res 2000, 2:249-251.
19. Makrygiannakis D, Af Klint E, Lundberg IE, Lofberg R, Ulfgren AK,
Klareskog L, Catrina AI: Citrullination is an inflammation-
dependent process. Ann Rheum Dis 2006, 65:1219-1222.
20. Vossenaar ER, Nijenhuis S, Helsen MM, van der Heijden A,
Senshu T, van den Berg WB, van Venrooij WJ, Joosten LA: Citrul-
lination of synovial proteins in murine models of rheumatoid
arthritis. Arthritis Rheum 2003, 48:2489-2500.
21. Lopez-Hoyos M, Marquina R, Tamayo E, Gonzalez-Rojas J, Izui S,
Merino R, Merino J: Defects in the regulation of B cell apopto-
sis are required for the production of citrullinated peptide
autoantibodies in mice. Arthritis Rheum 2003, 48:2353-2361.
22. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson
WH, Holers VM: Antibodies against citrullinated proteins
enhance tissue injury in experimental autoimmune arthritis. J
Clin Invest 2006, 116:961-973.
23. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA: The impact
of glycosylation on the biological function and structure of
human immunoglobulins. Annu Rev Immunol 2007, 25:21-50.
24. Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stan-
worth D, Rademacher TW, Mizuochi T, Taniguchi T, Matsuta K, et
al.: Association of rheumatoid arthritis and primary osteo-
arthritis with changes in the glycosylation pattern of total
serum IgG. Nature 1985, 316:452-457.
25. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim
RB: Glycosylation changes of IgG associated with rheumatoid
arthritis can activate complement via the mannose-binding
protein. Nat Med 1995, 1:237-243.
26. Rook GA, Steele J, Brealey R, Whyte A, Isenberg D, Sumar N,
Nelson JL, Bodman KB, Young A, Roitt IM, et al.: Changes in IgG
glycoform levels are associated with remission of arthritis
during pregnancy. J Autoimmun 1991, 4:779-794.
27. Rademacher TW, Williams P, Dwek RA: Agalactosyl glycoforms
of IgG autoantibodies are pathogenic. Proc Natl Acad Sci USA
1994, 91:6123-6127.
28. Kaneko Y, Nimmerjahn F, Ravetch JV: Anti-inflammatory activity
of immunoglobulin G resulting from Fc sialylation. Science
2006, 313:670-673.
29. Trentham DE, Townes AS, Kang AH: Autoimmunity to type II
collagen an experimental model of arthritis. J Exp Med 1977,
146:857-868.
30. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B:
Immunisation against heterologous type II collagen induces
arthritis in mice. Nature 1980, 283:666-668.
31. Cathcart ES, Hayes KC, Gonnerman WA, Lazzari AA, Franzblau
C: Experimental arthritis in a nonhuman primate. I. Induction
by bovine type II collagen. Lab Invest 1986, 54:26-31.
32. Yoo TJ, Kim SY, Stuart JM, Floyd RA, Olson GA, Cremer MA,
Kang AH: Induction of arthritis in monkeys by immunization
with type II collagen. J Exp Med 1988, 168:777-782.
33. Tarkowski A, Klareskog L, Carlsten H, Herberts P, Koopman WJ:
Secretion of antibodies to types I and II collagen by synovial
tissue cells in patients with rheumatoid arthritis. Arthritis
Rheum 1989, 32:1087-1092.
34. Terato K, Shimozuru Y, Katayama K, Takemitsu Y, Yamashita I,
Miyatsu M, Fujii K, Sagara M, Kobayashi S, Goto M, et al.: Speci-
ficity of antibodies to type II collagen in rheumatoid arthritis.
Arthritis Rheum 1990, 33:1493-1500.
35. Kim HJ, Krenn V, Steinhauser G, Berek C: Plasma cell develop-
ment in synovial germinal centers in patients with rheumatoid
and reactive arthritis. J Immunol 1999, 162:3053-3062.
36. Cook AD, Gray R, Ramshaw J, Mackay IR, Rowley MJ: Antibodies
against the CB10 fragment of type II collagen in rheumatoid
arthritis. Arthritis Res Ther 2004, 6:R477-483.
37. Holmdahl R, Rubin K, Klareskog L, Larsson E, Wigzell H: Charac-
terization of the antibody response in mice with type II colla-
gen-induced arthritis, using monoclonal anti-type II collagen
antibodies. Arthritis Rheum 1986, 29:400-410.
38. Holmdahl R, Mo JA, Jonsson R, Karlstrom K, Scheynius A: Multi-
ple epitopes on cartilage type II collagen are accessible for
antibody binding in vivo. Autoimmunity 1991, 10:27-34.
39. Mo JA, Bona CA, Holmdahl R: Variable region gene selection of
immunoglobulin G-expressing B cells with specificity for a
defined epitope on type II collagen. Eur J Immunol 1993, 23:
2503-2510.
Arthritis Research & Therapy    Vol 8 No 6 Nandakumar et al.
Page 8 of 11
(page number not for citation purposes)40. Mo JA, Scheynius A, Nilsson S, Holmdahl R: Germline-encoded
IgG antibodies bind mouse cartilage in vivo: epitope- and idio-
type-specific binding and inhibition. Scand J Immunol 1994,
39:122-130.
41. Mo JA, Holmdahl R: The B cell response to autologous type II
collagen: biased V gene repertoire with V gene sharing and
epitope shift. J Immunol 1996, 157:2440-2448.
42. Karlsson R, Mo JA, Holmdahl R: Binding of autoreactive mouse
anti-type II collagen antibodies derived from the primary and
the secondary immune response investigated with the
biosensor technique. J Immunol Methods 1995, 188:63-71.
43. Schulte S, Unger C, Mo JA, Wendler O, Bauer E, Frischholz S,
von der Mark K, Kalden JR, Holmdahl R, Burkhardt H: Arthritis-
related B cell epitopes in collagen II are conformation-depen-
dent and sterically privileged in accessible sites of cartilage
collagen fibrils. J Biol Chem 1998, 273:1551-1561.
44. Bajtner E, Nandakumar KS, Engstrom A, Holmdahl R: Chronic
development of collagen-induced arthritis is associated with
arthritogenic antibodies against specific epitopes on type II
collagen. Arthritis Res Ther 2005, 7:R1148-1157.
45. Nandakumar KS, Andren M, Martinsson P, Bajtner E, Hellstrom S,
Holmdahl R, Kleinau S: Induction of arthritis by single mono-
clonal IgG anti-collagen type II antibodies and enhancement
of arthritis in mice lacking inhibitory FcgammaRIIB. Eur J
Immunol 2003, 33:2269-2277.
46. Nandakumar KS, Backlund J, Vestberg M, Holmdahl R: Collagen
type II (CII)-specific antibodies induce arthritis in the absence
of T or B cells but the arthritis progression is enhanced by
CII-reactive T cells. Arthritis Res Ther 2004, 6:R544-550.
47. Nandakumar KS, Holmdahl R: Efficient promotion of collagen
antibody induced arthritis (CAIA) using four monoclonal anti-
bodies specific for the major epitopes recognized in both col-
lagen induced arthritis and rheumatoid arthritis. J Immunol
Methods 2005, 304:126-136.
48. Amirahmadi SF, Pho MH, Gray RE, Crombie DE, Whittingham SF,
Zuasti BB, Van Damme MP, Rowley MJ: An arthritogenic mono-
clonal antibody to type II collagen, CII-C1, impairs cartilage
formation by cultured chondrocytes. Immunol Cell Biol 2004,
82:427-434.
49. Gray RE, Seng N, Mackay IR, Rowley MJ: Measurement of anti-
bodies to collagen II by inhibition of collagen fibril formation
in vitro. J Immunol Methods 2004, 285:55-61.
50. Amirahmadi SF, Whittingham S, Crombie DE, Nandakumar KS,
Holmdahl R, Mackay IR, van Damme MP, Rowley MJ: Arthrito-
genic anti-type II collagen antibodies are pathogenic for carti-
lage-derived chondrocytes independent of inflammatory cells.
Arthritis Rheum 2005, 52:1897-1906.
51. Crombie DE, Turer M, Zuasti BB, Wood B, McNaughton D, Nan-
dakumar KS, Holmdahl R, M-P VD, Rowley MJ: Destructive
effects of murine arthritogenic antibodies to type II collagen
on cartilage explants in vitro. Arthritis Res Ther 2005, 7:R927-
R937.
52. Holmdahl R, Jansson L, Larsson A, Jonsson R: Arthritis in DBA/1
mice induced with passively transferred type II collagen
immune serum. Immunohistopathology and serum levels of
anti-type II collagen auto-antibodies. Scand J Immunol 1990,
31:147-157.
53. Wooley PH, Luthra HS, Singh SK, Huse AR, Stuart JM, David CS:
Passive transfer of arthritis to mice by injection of human
anti-type II collagen antibody. Mayo Clin Proc 1984, 59:737-
743.
54. Lee EK, Kang SM, Paik DJ, Kim JM, Youn J: Essential roles of
Toll-like receptor-4 signaling in arthritis induced by type II col-
lagen antibody and LPS. Int Immunol 2005, 17:325-333.
55. Carlsen S, Nandakumar KS, Holmdahl R: Type IX collagen defi-
ciency enhances the binding of cartilage-specific antibodies
and arthritis severity. Arthritis Res Ther 2006, 8:R102.
56. Kagari T, Doi H, Shimozato T: The importance of IL-1 beta and
TNF-alpha, and the noninvolvement of IL-6, in the develop-
ment of monoclonal antibody-induced arthritis. J Immunol
2002, 169:1459-1466.
57. Arend WP, Dayer JM: Inhibition of the production and effects
of interleukin-1 and tumor necrosis factor alpha in rheuma-
toid arthritis. Arthritis Rheum 1995, 38:151-160.
58. Feldmann M, Brennan FM, Williams RO, Woody JN, Maini RN:
The transfer of a laboratory based hypothesis to a clinically
useful therapy: the development of anti-TNF therapy of
rheumatoid arthritis. Best Pract Res Clin Rheumatol 2004, 18:
59-80.
59. Marinova-Mutafchieva L, Williams RO, Mason LJ, Mauri C, Feld-
mann M, Maini RN: Dynamics of proinflammatory cytokine
expression in the joints of mice with collagen-induced arthri-
tis (CIA). Clin Exp Immunol 1997, 107:507-512.
60. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB: Anti-
cytokine treatment of established type II collagen-induced
arthritis in DBA/1 mice. A comparative study using anti-TNF
alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 1996,
39:797-809.
61. Langdon C, Kerr C, Hassen M, Hara T, Arsenault AL, Richards
CD: Murine oncostatin M stimulates mouse synovial fibrob-
lasts  in vitro and induces inflammation and destruction in
mouse joints in vivo. Am J Pathol 2000, 157:1187-1196.
62. Plater-Zyberk C, Buckton J, Thompson S, Spaull J, Zanders E,
Papworth J, Life PF: Amelioration of arthritis in two murine
models using antibodies to oncostatin M. Arthritis Rheum
2001, 44:2697-2702.
63. Wallace PM, MacMaster JF, Rouleau KA, Brown TJ, Loy JK, Don-
aldson KL, Wahl AF: Regulation of inflammatory responses by
oncostatin M. J Immunol 1999, 162:5547-5555.
64. Ichihara M, Hara T, Kim H, Murate T, Miyajima A: Oncostatin M
and leukemia inhibitory factor do not use the same functional
receptor in mice. Blood 1997, 90:165-173.
65. Wang J, Fathman JW, Lugo-Villarino G, Scimone L, von Andrian
U, Dorfman DM, Glimcher LH: Transcription factor T-bet regu-
lates inflammatory arthritis through its function in dendritic
cells. J Clin Invest 2006, 116:414-421.
66. Svensson L, Nandakumar KS, Johansson A, Jansson L, Holmdahl
R: IL-4-deficient mice develop less acute but more chronic
relapsing collagen-induced arthritis. Eur J Immunol 2002, 32:
2944-2953.
67. Nandakumar KS, Holmdahl R: Arthritis induced with cartilage-
specific antibodies is IL-4-dependent. Eur J Immunol 2006, 36:
1608-1618.
68. Johansson AC, Hansson AS, Nandakumar KS, Backlund J, Holm-
dahl R: IL-10-deficient B10.Q mice develop more severe colla-
gen-induced arthritis, but are protected from arthritis induced
with anti-type II collagen antibodies. J Immunol 2001,  167:
3505-3512.
69. Treschow AP, Teige I, Nandakumar KS, Holmdahl R, Issazadeh-
Navikas S: Stromal cells and osteoclasts are responsible for
exacerbated collagen-induced arthritis in interferon-beta-defi-
cient mice. Arthritis Rheum 2005, 52:3739-3748.
70. Zhou JS, Friend DS, Lee DM, Li L, Austen KF, Katz HR: gp49B1
deficiency is associated with increases in cytokine and
chemokine production and severity of proliferative synovitis
induced by anti-type II collagen mAb. Eur J Immunol 2005, 35:
1530-1538.
71. Murata K, Inami M, Hasegawa A, Kubo S, Kimura M, Yamashita M,
Hosokawa H, Nagao T, Suzuki K, Hashimoto K, et al.: CD69-null
mice protected from arthritis induced with anti-type II colla-
gen antibodies. Int Immunol 2003, 15:987-992.
72. Lamana A, Sancho D, Cruz-Adalia A, del Hoyo GM, Herrera AM,
Feria M, Diaz-Gonzalez F, Gomez M, Sanchez-Madrid F: The role
of CD69 in acute neutrophil-mediated inflammation. Eur J
Immunol 2006, 36:2632-2638.
73. Sehnert B, Cavcic A, Bohm B, Kalden JR, Nandakumar KS, Holm-
dahl R, Burkhardt H: Antileukoproteinase: modulation of neu-
trophil function and therapeutic effects on anti-type II
collagen antibody-induced arthritis. Arthritis Rheum 2004, 50:
2347-2359.
74. Sehnert B, Gierer P, Ibrahim S, Kuhl A, Voll R, Nandakumar KS,
Holmdahl R, Hallmann R, Vollmar B, Burkhardt H: Modulation of
granulocyte-endothelium interactions by antileukoproteinase:
inhibition of anti-type II collagen antibody-induced leukocyte
attachment to the synovial endothelium. Arthritis Res Ther
2006, 8:R95.
75. Lange F, Bajtner E, Rintisch C, Nandakumar KS, Sack U, Holm-
dahl R: Methotrexate ameliorates T cell dependent autoim-
mune arthritis and encephalomyelitis but not antibody
induced or fibroblast induced arthritis. Ann Rheum Dis 2005,
64:599-605.
76. Miyazawa S, Nishida K, Komiyama T, Nakae Y, Takeda K, Yorim-
itsu M, Kitamura A, Kunisada T, Ohtsuka A, Inoue H: Novel trans-
dermal photodynamic therapy using ATX-S10.Na(II) induces
Available online http://arthritis-research.com/content/8/6/223
Page 9 of 11
(page number not for citation purposes)apoptosis of synovial fibroblasts and ameliorates collagen
antibody-induced arthritis in mice. Rheumatol Int 2006,  26:
717-725.
77. Ichiyama H, Onodera S, Nishihira J, Ishibashi T, Nakayama T,
Minami A, Yasuda K, Tohyama H: Inhibition of joint inflamma-
tion and destruction induced by anti-type II collagen anti-
body/lipopolysaccharide (LPS)-induced arthritis in mice due
to deletion of macrophage migration inhibitory factor (MIF).
Cytokine 2004, 26:187-194.
78. Chintalacharuvu SR, Wang JX, Giaconia JM, Venkataraman C: An
essential role for CCL3 in the development of collagen anti-
body-induced arthritis. Immunol Lett 2005, 100:202-204.
79. Li J, Ny A, Leonardsson G, Nandakumar KS, Holmdahl R, Ny T:
The plasminogen activator/plasmin system is essential for
development of the joint inflammatory phase of collagen type
II-induced arthritis. Am J Pathol 2005, 166:783-792.
80. Adkison AM, Raptis SZ, Kelley DG, Pham CT: Dipeptidyl pepti-
dase I activates neutrophil-derived serine proteases and reg-
ulates the development of acute experimental arthritis. J Clin
Invest 2002, 109:363-371.
81. de Fougerolles AR, Sprague AG, Nickerson-Nutter CL, Chi-Rosso
G, Rennert PD, Gardner H, Gotwals PJ, Lobb RR, Koteliansky VE:
Regulation of inflammation by collagen-binding integrins
alpha1beta1 and alpha2beta1 in models of hypersensitivity
and arthritis. J Clin Invest 2000, 105:721-729.
82. Kato H, Nishida K, Yoshida A, Takada I, McCown C, Matsuo M,
Murakami T, Inoue H: Effect of NOS2 gene deficiency on the
development of autoantibody mediated arthritis and subse-
quent articular cartilage degeneration. J Rheumatol 2003, 30:
247-255.
83. Myers LK, Kang AH, Postlethwaite AE, Rosloniec EF, Morham
SG, Shlopov BV, Goorha S, Ballou LR: The genetic ablation of
cyclooxygenase 2 prevents the development of autoimmune
arthritis. Arthritis Rheum 2000, 43:2687-2693.
84. McCoy JM, Wicks JR, Audoly LP: The role of prostaglandin E2
receptors in the pathogenesis of rheumatoid arthritis. J Clin
Invest 2002, 110:651-658.
85. Kamei D, Yamakawa K, Takegoshi Y, Mikami-Nakanishi M,
Nakatani Y, Oh-Ishi S, Yasui H, Azuma Y, Hirasawa N, Ohuchi K,
et al.: Reduced pain hypersensitivity and inflammation in mice
lacking microsomal prostaglandin e synthase-1. J Biol Chem
2004, 279:33684-33695.
86. Pulichino AM, Rowland S, Wu T, Clark P, Xu D, Mathieu MC,
Riendeau D, Audoly LP: Prostacyclin antagonism reduces pain
and inflammation in rodent models of hyperalgesia and
chronic arthritis. J Pharmacol Exp Ther 2006, 319:1043-1050.
87. Itoh T, Matsuda H, Tanioka M, Kuwabara K, Itohara S, Suzuki R:
The role of matrix metalloproteinase-2 and matrix metallopro-
teinase-9 in antibody-induced arthritis. J Immunol 2002, 169:
2643-2647.
88. Han Z, Chang L, Yamanishi Y, Karin M, Firestein GS: Joint
damage and inflammation in c-Jun N-terminal kinase 2 knock-
out mice with passive murine collagen-induced arthritis.
Arthritis Rheum 2002, 46:818-823.
89. Yumoto K, Ishijima M, Rittling SR, Tsuji K, Tsuchiya Y, Kon S,
Nifuji A, Uede T, Denhardt DT, Noda M: Osteopontin deficiency
protects joints against destruction in anti-type II collagen anti-
body-induced arthritis in mice. Proc Natl Acad Sci USA 2002,
99:4556-4561.
90. Blom T, Franzen A, Heinegard D, Holmdahl R: Comment on “The
influence of the proinflammatory cytokine, osteopontin, on
autoimmune demyelinating disease”. Science  2003,  299:
1845; author reply 1845.
91. Abbas AK, Lichtman AH, Pober JS: Immune-mediated tissue
injury and disease. In Cellular and Molecular Immunology. 4th
edition. Edited by Abbas AK, Lichtman AH, Pober JS. Philadel-
phia: Saunders; 1997:423-438.
92. Colten HR: Immunology. Drawing a double-edged sword.
Nature 1994, 371:474-475.
93. Ravetch JV, Clynes RA: Divergent roles for Fc receptors and
complement in vivo. Annu Rev Immunol 1998, 16:421-432.
94. Quigg RJ, Lim A, Haas M, Alexander JJ, He C, Carroll MC:
Immune complex glomerulonephritis in C4- and C3-deficient
mice. Kidney Int 1998, 53:320-330.
95. Kagari T, Tanaka D, Doi H, Shimozato T: Essential role of Fc
gamma receptors in anti-type II collagen antibody-induced
arthritis. J Immunol 2003, 170:4318-4324.
96. Tan Sardjono C, Mottram PL, van de Velde NC, Powell MS,
Power D, Slocombe RF, Wicks IP, Campbell IK, McKenzie SE,
Brooks M, et al.: Development of spontaneous multisystem
autoimmune disease and hypersensitivity to antibody-
induced inflammation in Fcgamma receptor IIa-transgenic
mice. Arthritis Rheum 2005, 52:3220-3229.
97. Hietala MA, Nandakumar KS, Persson L, Fahlen S, Holmdahl R,
Pekna M: Complement activation by both classical and alter-
native pathways is critical for the effector phase of arthritis.
Eur J Immunol 2004, 34:1208-1216.
98. Wang Y, Rollins SA, Madri JA, Matis LA: Anti-C5 monoclonal
antibody therapy prevents collagen-induced arthritis and
ameliorates established disease. Proc Natl Acad Sci USA
1995, 92:8955-8959.
99. Wang Y, Kristan J, Hao L, Lenkoski CS, Shen Y, Matis LA: A role
for complement in antibody-mediated inflammation: C5-defi-
cient DBA/1 mice are resistant to collagen-induced arthritis. J
Immunol 2000, 164:4340-4347.
100.Grant EP, Picarella D, Burwell T, Delaney T, Croci A, Avitahl N,
Humbles AA, Gutierrez-Ramos JC, Briskin M, Gerard C, et al.:
Essential role for the c5a receptor in regulating the effector
phase of synovial infiltration and joint destruction in experi-
mental arthritis. J Exp Med 2002, 196:1461-1471.
101.Kerwar SS, Gordon S, McReynolds RA, Oronsky AL: Passive
transfer of arthritis by purified anticollagen immunoglobulin:
localization of 125I-labeled antibody. Clin Immunol
Immunopathol 1983, 29:318-321.
102.Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli
SS, Espinola R, Xiaowei LE, Mao D, Vialpando CG, et al.: Com-
plement C3 activation is required for antiphospholipid anti-
body-induced fetal loss. J Exp Med 2002, 195:211-220.
103.Smith GP, Smith RA: Membrane-targeted complement inhibitors.
Mol Immunol 2001, 38:249-255.
104.Watson WC, Brown PS, Pitcock JA, Townes AS: Passive trans-
fer studies with type II collagen antibody in B10.D2/old and
new line and C57Bl/6 normal and beige (Chediak-Higashi)
strains: evidence of important roles for C5 and multiple
inflammatory cell types in the development of erosive arthri-
tis. Arthritis Rheum 1987, 30:460-465.
105.Gerard C, Gerard NP: C5A anaphylatoxin and its seven trans-
membrane-segment receptor. Annu Rev Immunol 1994,  12:
775-808.
106.Konteatis ZD, Siciliano SJ, Van Riper G, Molineaux CJ, Pandya S,
Fischer P, Rosen H, Mumford RA, Springer MS: Development of
C5a receptor antagonists. Differential loss of functional
responses. J Immunol 1994, 153:4200-4205.
107.Jose PJ, Moss IK, Maini RN, Williams TJ: Measurement of the
chemotactic complement fragment C5a in rheumatoid syn-
ovial fluids by radioimmunoassay: role of C5a in the acute
inflammatory phase. Ann Rheum Dis 1990, 49:747-752.
108.Heller T, Hennecke M, Baumann U, Gessner JE, zu Vilsendorf AM,
Baensch M, Boulay F, Kola A, Klos A, Bautsch W, et al.: Selec-
tion of a C5a receptor antagonist from phage libraries attenu-
ating the inflammatory response in immune complex disease
and ischemia/reperfusion injury. J Immunol 1999,  163:985-
994.
109.Schindler R, Gelfand JA, Dinarello CA: Recombinant C5a stimu-
lates transcription rather than translation of interleukin-1
(IL-1) and tumor necrosis factor: translational signal provided
by lipopolysaccharide or IL-1 itself. Blood  1990,  76:1631-
1638.
110.Takabayashi T, Vannier E, Clark BD, Margolis NH, Dinarello CA,
Burke JF, Gelfand JA: A new biologic role for C3a and C3a
desArg: regulation of TNF-alpha and IL-1 beta synthesis. J
Immunol 1996, 156:3455-3460.
111.Shushakova N, Skokowa J, Schulman J, Baumann U, Zwirner J,
Schmidt RE, Gessner JE: C5a anaphylatoxin is a major regula-
tor of activating versus inhibitory FcgammaRs in immune
complex-induced lung disease. J Clin Invest 2002, 110:1823-
1830.
112.Hawlisch H, Belkaid Y, Baelder R, Hildeman D, Gerard C, Kohl J:
C5a negatively regulates toll-like receptor 4-induced immune
responses. Immunity 2005, 22:415-426.
113.Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C,
Mathis D: Organ-specific disease provoked by systemic
autoimmunity. Cell 1996, 87:811-822.
114.Ji H, Gauguier D, Ohmura K, Gonzalez A, Duchatelle V, Danoy P,
Arthritis Research & Therapy    Vol 8 No 6 Nandakumar et al.
Page 10 of 11
(page number not for citation purposes)Garchon HJ, Degott C, Lathrop M, Benoist C, et al.: Genetic
influences on the end-stage effector phase of arthritis. J Exp
Med 2001, 194:321-330.
115.Matsumoto I, Staub A, Benoist C, Mathis D: Arthritis provoked
by linked T and B cell recognition of a glycolytic enzyme.
Science 1999, 286:1732-1735.
116.Basu D, Horvath S, Matsumoto I, Fremont DH, Allen PM: Molecu-
lar basis for recognition of an arthritic peptide and a foreign
epitope on distinct MHC molecules by a single TCR. J Immunol
2000, 164:5788-5796.
117.Ohmura K, Nguyen LT, Locksley RM, Mathis D, Benoist C: Inter-
leukin-4 can be a key positive regulator of inflammatory
arthritis. Arthritis Rheum 2005, 52:1866-1875.
118.Kyburz D, Carson DA, Corr M: The role of CD40 ligand and
tumor necrosis factor alpha signaling in the transgenic K/BxN
mouse model of rheumatoid arthritis. Arthritis Rheum 2000,
43:2571-2577.
119.Schubert D, Maier B, Morawietz L, Krenn V, Kamradt T: Immu-
nization with glucose-6-phosphate isomerase induces T cell-
dependent peripheral polyarthritis in genetically unaltered
mice. J Immunol 2004, 172:4503-4509.
120.Bockermann R, Schubert D, Kamradt T, Holmdahl R: Induction of
a B-cell-dependent chronic arthritis with glucose-6-phos-
phate isomerase. Arthritis Res Ther 2005, 7:R1316-1324.
121.Korganow AS, Ji H, Mangialaio S, Duchatelle V, Pelanda R, Martin
T, Degott C, Kikutani H, Rajewsky K, Pasquali JL, et al.: From sys-
temic T cell self-reactivity to organ-specific autoimmune
disease via immunoglobulins. Immunity 1999, 10:451-461.
122.Maccioni M, Zeder-Lutz G, Huang H, Ebel C, Gerber P, Hergueux
J, Marchal P, Duchatelle V, Degott C, van Regenmortel M, et al.:
Arthritogenic monoclonal antibodies from K/BxN mice. J Exp
Med 2002, 195:1071-1077.
123.Wipke BT, Wang Z, Kim J, McCarthy TJ, Allen PM: Dynamic visu-
alization of a joint-specific autoimmune response through
positron emission tomography. Nat Immunol 2002, 3:366-372.
124.Wipke BT, Wang Z, Nagengast W, Reichert DE, Allen PM:
Staging the initiation of autoantibody-induced arthritis: a criti-
cal role for immune complexes. J Immunol 2004, 172:7694-
7702.
125.Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner
MB:  Mast cells: a cellular link between autoantibodies and
inflammatory arthritis. Science 2002, 297:1689-1692.
126.Wipke BT, Allen PM: Essential role of neutrophils in the initia-
tion and progression of a murine model of rheumatoid arthri-
tis. J Immunol 2001, 167:1601-1608.
127.Kim ND, Chou RC, Seung E, Tager AM, Luster AD: A unique
requirement for the leukotriene B4 receptor BLT1 for neu-
trophil recruitment in inflammatory arthritis. J Exp Med 2006,
203:829-835.
128.Bruhns P, Samuelsson A, Pollard JW, Ravetch JV: Colony-stimu-
lating factor-1-dependent macrophages are responsible for
IVIG protection in antibody-induced autoimmune disease.
Immunity 2003, 18:573-581.
129.Solomon S, Rajasekaran N, Jeisy-Walder E, Snapper SB, Illges H:
A crucial role for macrophages in the pathology of K/B x N
serum-induced arthritis. Eur J Immunol 2005, 35:3064-3073.
130.Scatizzi JC, Hutcheson J, Bickel E, Woods JM, Klosowska K,
Moore TL, Haines GK 3rd, Perlman H: p21Cip1 is required for
the development of monocytes and their response to serum
transfer-induced arthritis. Am J Pathol 2006, 168:1531-1541.
131.Corr M, Crain B: The role of FcgammaR signaling in the K/B x
N serum transfer model of arthritis. J Immunol 2002,
169:6604-6609.
132.Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C,
Gravallese E, Mathis D, Benoist C: Critical roles for interleukin 1
and tumor necrosis factor alpha in antibody-induced arthritis.
J Exp Med 2002, 196:77-85.
133.Choe JY, Crain B, Wu SR, Corr M: Interleukin 1 receptor
dependence of serum transferred arthritis can be circum-
vented by toll-like receptor 4 signaling. J Exp Med 2003, 197:
537-542.
134.Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, Boackle SA,
Takahashi K, Holers VM, Walport M, Gerard C, et al.: Arthritis
critically dependent on innate immune system players. Immu-
nity 2002, 16:157-168.
135.Solomon S, Kolb C, Mohanty S, Jeisy-Walder E, Preyer R, Scholl-
horn V, Illges H: Transmission of antibody-induced arthritis is
independent of complement component 4 (C4) and the com-
plement receptors 1 and 2 (CD21/35). Eur J Immunol 2002,
32:644-651.
136.Akilesh S, Petkova S, Sproule TJ, Shaffer DJ, Christianson GJ,
Roopenian D: The MHC class I-like Fc receptor promotes
humorally mediated autoimmune disease. J Clin Invest 2004,
113:1328-1333.
137.Kim HY, Kim HJ, Min HS, Kim S, Park WS, Park SH, Chung DH:
NKT cells promote antibody-induced joint inflammation by
suppressing transforming growth factor beta1 production. J
Exp Med 2005, 201:41-47.
138.Ohmura K, Johnsen A, Ortiz-Lopez A, Desany P, Roy M, Besse W,
Rogus J, Bogue M, Puech A, Lathrop M, et al.: Variation in IL-
1beta gene expression is a major determinant of genetic dif-
ferences in arthritis aggressivity in mice. Proc Natl Acad Sci
USA 2005, 102:12489-12494.
139.Siragam V, Brinc D, Crow AR, Song S, Freedman J, Lazarus AH:
Can antibodies with specificity for soluble antigens mimic the
therapeutic effects of intravenous IgG in the treatment of
autoimmune disease? J Clin Invest 2005, 115:155-160.
140.Binstadt BA, Patel PR, Alencar H, Nigrovic PA, Lee DM,
Mahmood U, Weissleder R, Mathis D, Benoist C: Particularities
of the vasculature can promote the organ specificity of
autoimmune attack. Nat Immunol 2006, 7:284-292.
141.Scatizzi JC, Bickel E, Hutcheson J, Haines GK 3rd, Perlman H:
Bim deficiency leads to exacerbation and prolongation of joint
inflammation in experimental arthritis. Arthritis Rheum 2006,
54:3182-3193.
142.Schaller M, Burton DR, Ditzel HJ: Autoantibodies to GPI in
rheumatoid arthritis: linkage between an animal model and
human disease. Nat Immunol 2001, 2:746-753.
143.Nandakumar KS, Holmdahl R: A genetic contamination in MHC-
congenic mouse strains reveals a locus on chromosome 10
that determines autoimmunity and arthritis susceptibility. Eur
J Immunol 2005, 35:1275-1282.
144.Johannesson M, Karlsson J, Wernhoff P, Nandakumar KS,
Lindqvist AK, Olsson L, Cook AD, Andersson A, Holmdahl R:
Identification of epistasis through a partial advanced inter-
cross reveals three arthritis loci within the Cia5 QTL in mice.
Genes Immun 2005, 6:175-185.
145.Blake JA, Richardson JE, Bult CJ, Kadin JA, Eppig JT: MGD: the
Mouse Genome Database. Nucleic Acids Res 2003, 31:193-
195.
146.Encinas JA, Wicker LS, Peterson LB, Mukasa A, Teuscher C,
Sobel R, Weiner HL, Seidman CE, Seidman JG, Kuchroo VK: QTL
influencing autoimmune diabetes and encephalomyelitis map
to a 0.15-cM region containing Il2. Nat Genet 1999, 21:158-
160.
147.Mitchison A: Partitioning of genetic variation between regula-
tory and coding gene segments: the predominance of soft-
ware variation in genes encoding introvert proteins.
Immunogenetics 1997, 46:46-52.
148.Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV: FcgammaRIV: a
novel FcR with distinct IgG subclass specificity. Immunity
2005, 23:41-51.
Available online http://arthritis-research.com/content/8/6/223
Page 11 of 11
(page number not for citation purposes)